Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arpraziquantel Dose-Finding in Pediatric Schistosomiasis
NCT02806232Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of levopraziquantel in schistosomiasis mansoni (9 arms), sponsored by Merck KGaA. Primary endpoint: Number of Participants With Clinical Cure Determined by Kato-Katz Method. Started Jun 2016; status: completed.
02
Drugs
levopraziquantel
03
Conditions
schistosomiasis mansoni
Beyond the preview
Go deeper on NCT02806232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806232.